Articles from Vogenx, Inc.

RALEIGH, NC / ACCESS Newswire / August 11, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at the high end of the range at a public offering price of $13.00 per share. All of the shares are being offered by Vogenx. The gross proceeds to Vogenx from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $81.3 million.